HCW Biologics (NASDAQ:HCWB – Get Free Report) and Cardio Diagnostics (NASDAQ:CDIO – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership.
Insider and Institutional Ownership
3.0% of HCW Biologics shares are held by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are held by institutional investors. 9.1% of HCW Biologics shares are held by company insiders. Comparatively, 9.0% of Cardio Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for HCW Biologics and Cardio Diagnostics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| HCW Biologics | 1 | 0 | 1 | 0 | 2.00 |
| Cardio Diagnostics | 1 | 0 | 0 | 0 | 1.00 |
Risk & Volatility
HCW Biologics has a beta of 2.41, meaning that its share price is 141% more volatile than the S&P 500. Comparatively, Cardio Diagnostics has a beta of 2.29, meaning that its share price is 129% more volatile than the S&P 500.
Earnings and Valuation
This table compares HCW Biologics and Cardio Diagnostics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| HCW Biologics | $50,000.00 | 71.68 | -$7.96 million | ($27.60) | -0.06 |
| Cardio Diagnostics | $10,000.00 | 553.52 | -$6.50 million | ($2.92) | -0.64 |
Cardio Diagnostics has lower revenue, but higher earnings than HCW Biologics. Cardio Diagnostics is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares HCW Biologics and Cardio Diagnostics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| HCW Biologics | -83.03% | -262.33% | -34.90% |
| Cardio Diagnostics | -43,133.33% | -82.28% | -76.03% |
Summary
HCW Biologics beats Cardio Diagnostics on 9 of the 14 factors compared between the two stocks.
About HCW Biologics
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
About Cardio Diagnostics
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
Receive News & Ratings for HCW Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCW Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
